The key of Laboratory Precision Medicine for Severe Autoimmune Diseases of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China.
J Cell Mol Med. 2017 Oct;21(10):2317-2328. doi: 10.1111/jcmm.13153. Epub 2017 Mar 23.
EZH2, a histone H3 lysine-27-specific methyltransferase, is involved in diverse physiological and pathological processes including cell proliferation and differentiation. However, the role of EZH2 in liver fibrosis is largely unknown. In this study, it was identified that EZH2 promoted Wnt pathway-stimulated fibroblasts in vitro and in vivo by repressing Dkk-1, which is a Wnt pathway antagonist. The expression of EZH2 was increased in CCl -induced rat liver and primary HSCs as well as TGF-β1-treated HSC-T6, whereas the expression of Dkk1 was reduced. Silencing of EZH2 prevented TGF-β1-induced proliferation of HSC-T6 cells and the expression of α-SMA. In addition, knockdown of Dkk1 promoted TGF-β1-induced activation of HSCs. Moreover, silencing of EZH2 could restore the repression of Dkk-1 through trimethylation of H3K27me3 in TGF-β1-treated HSC-T6 cells. Interestingly, inhibition of EZH2 had almost no effect on the activation of HSC when Dkk1 was silenced. Collectively, EZH2-mediated repression of Dkk1 promotes the activation of Wnt/β-catenin pathway, which is an essential event for HSC activation.
EZH2 是一种组蛋白 H3 赖氨酸-27 特异性甲基转移酶,参与多种生理和病理过程,包括细胞增殖和分化。然而,EZH2 在肝纤维化中的作用在很大程度上尚不清楚。在这项研究中,研究人员发现 EZH2 通过抑制 Wnt 通路拮抗剂 Dkk-1 促进体外和体内 Wnt 通路刺激的成纤维细胞。在 CCl4 诱导的大鼠肝和原代 HSCs 以及 TGF-β1 处理的 HSC-T6 中,EZH2 的表达增加,而 Dkk1 的表达减少。沉默 EZH2 可防止 TGF-β1 诱导的 HSC-T6 细胞增殖和α-SMA 的表达。此外,Dkk1 的敲低促进了 TGF-β1 诱导的 HSCs 的激活。此外,沉默 EZH2 可通过 TGF-β1 处理的 HSC-T6 细胞中 H3K27me3 的三甲基化来恢复对 Dkk-1 的抑制。有趣的是,当 Dkk1 被沉默时,抑制 EZH2 对 HSC 的激活几乎没有影响。总之,EZH2 介导的 Dkk1 抑制促进了 Wnt/β-catenin 通路的激活,这是 HSC 激活的一个重要事件。